Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s Lymphoma
CD47 is an immune modulator molecule overexpressed on cancer cells that sends inhibitory signals to macrophages. Binding of 5F9 to CD47 takes the brakes off macrophages enabling them to phagocytose, or swallow, tumor cells. In a Phase 1b study published in the
“There is a large unmet medical need for new therapies for DLBCL patients, particularly for those who are ineligible for current therapies because they have rapidly progressive disease and cannot wait for a therapy that requires an extended time to implement or who are frail and unable to withstand the side-effects of current therapies,” said
CD47 Blockade by Hu5F9-G4 combined with Rituximab in Non-Hodgkin’s Lymphoma. R Advani et al, N. Engl. J. Med. 379, 1711, 2018.
PD-L1 and tumor-associated macrophages in de novo DLBCL. R. McCord et al, Blood Advances 3, 531, 2019.
Tecentriq® (atezolizumab) and Rituxan® (rituximab) are registered trademarks of Genentech, a member of the
5F9 is a monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPα receptor on macrophages, thus blocking the “don’t eat me” signal used by cancer cells to avoid being ingested by macrophages. Forty Seven, Inc. is initially developing 5F9, an investigational medicine, for the treatment of patients with solid tumors, acute myeloid leukemia, non-Hodgkin’s lymphoma, ovarian cancer and colorectal cancer. 5F9 has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, two forms of B-cell non-Hodgkin’s lymphoma.
Forward Looking Statements:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing and success of Forty Seven’s collaboration with Genentech, the potential for 5F9 to be developed in combination with rituximab and atezolizumab to optimize the treatment of DLBCL patients whose tumors are associated with high levels of macrophages expressing PD-L1, Forty Seven’s plans to initiate a clinical trial for the triplet regimen of 5F9, rituximab and atezolizumab, the safety, tolerability and efficacy of 5F9, the overall advancement of 5F9 in clinical trials, Forty Seven’s plans to continue development of 5F9 in combination with rituximab and atezolizumab, as well as related timing for clinical trials of the same. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward looking statements. The potential product candidates that Forty Seven develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Forty Seven's stock price. Additional information concerning these and other risk factors affecting Forty Seven's business can be found in Forty Seven's periodic filings with the
For journalist enquiries please contact
For investor enquiries please contact
Source: Forty Seven, Inc.